Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer
01 Feb 2024
Cell TherapyFast TrackINDImmunotherapyClinical Study
SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
Continue Reading
Preview
Source: PRNewswire
Fast track is a process designed to facilitate development, and accelerate the review of drugs to treat serious or life-threatening conditions and fill an unmet medical need. This designation is anticipated to expedite the advancement of clinical trials and the registration of pharmaceutical products for marketing purposes.
BST02 has received approval from the FDA for Phase I/II clinical trial in October 2023 and has also been approved by the Center for Drug Evaluation (CDE) of the China National Drug Administration in January, 2024. This marks the first TIL cell therapy drug for liver cancer to progress to the clinical stage globally. Furthermore, another product from Biosyngen, BRG01, was granted fast track designation in July 2023.
Michelle Chen, co-founder and CEO of Biosyngen, expressed gratitude towards the FDA for acknowledging the company's fourth product. She emphasized the company's commitment to advancing cell therapy for cancer globally and providing innovative treatment solutions for diverse patient populations. Michelle reiterated Biosyngen's dedication to leveraging its advanced technology platforms to offer more effective and accessible treatment options for patients worldwide.
BST02, a T cell therapy based on the expansion of the patient's own tumor infiltrating lymphocytes, falls within the category of adoptive immune cell therapy technology. It holds promise for the treatment of all types of liver cancer, offering new hope for patients. In contrast to traditional TIL therapies, BST02 offers numerous benefits, including the ability to overcome distance constraints due to its cryopreserved form and the reduced need for high doses of interleukin-2.
SOURCE Biosyngen
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.